Mark Stenhouse, Board Observer & Advisor to Abivax, said: “I am impressed with the clinical profile of obefazimod and its potential to address unmet needs in the patient community ... recipients as a ...

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...

common share at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $1.81 per share. The combined offering price of each ...

This study involved 182 LockeT devices deployed in over 100 patients, with outstanding clinical results ... The company announced on October 25, 2024, the exercise of outstanding warrants resulting in ...

CalciMedica expects to enroll 150 patients with stage ... benefits of Auxora for the treatment of AP, AKI and AIPT; the potential for additional proceeds from the underwritten public offering if the ...

Additional information about the Company's Non-GAAP financial measures can be found under the caption "About Non-GAAP Financial Measures ... which is designed to aggregate patient data from across the ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

Russia has suffered record losses for a second consecutive day, Ukraine has claimed, as Vladimir Putin’s forces seek to ...

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...

MILWAUKEE - Thanksgiving will be here before we know it, and with that can come a conversation about gratitude with our kids.

(Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today ...